Earlier than expected: Johnson&Johnson in July will begin human trials of a vaccine against coronavirus

Johnson&Johnson announced on Wednesday, June 10, that an early human trial of a potential vaccine against the coronavirus will begin in the second half of July. This is much earlier than expected, the original forecast for the test was on Sept. This writes CNBC.

Раньше, чем ожидалось: Johnson&Johnson уже в июле начнет испытания на людях вакцины от коронавируса

Photo: Shutterstock

“Based on convincing preclinical data that we’ve seen so far, and interaction with regulatory authorities, we were able to accelerate the clinical development of our vaccine against SARS-CoV-2, Ad26.COV2-S,” said chief scientific officer of J&J Stoffels.

The company began the development of a vaccine against Covid-19 in January 2020.

It uses the same technology that is used to create an experimental Ebola vaccine, which was given to people in the Democratic Republic of the Congo at the end of 2019. It involves combining the genetic material of the coronavirus with a modified adenovirus, which is known to cause the common cold in people.

Recently, J&J said that if the vaccine would work well and be safe, the company will be able to produce 600 to 900 million doses by April 2021. On 10 June the company said it plans to supply more than 1 billion doses worldwide for 2021.

Early trials J&J will test his vaccine on 1045 healthy adults aged 18 to 55 years of age and adults aged 65 years and older. All this will take place in the United States and Belgium.

Johnson&Johnson is one of several companies that are developing potential vaccines for the prevention Covid-19.

According to the world health organization, as of June 2, is developed by at least 124 vaccines. At least 10 of them are already under clinical trials.

National institutes of health in conjunction with the biotech firm Moderna actively working to develop potential vaccines against Covid-19.

According to Dr. Anthony Fauci, Director of the National Institute of Allergy and infectious diseases, Moderna plans to attract about 30 000 people, when in July will begin the third phase of testing.




Educational program


Special projects